DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia (wAIHA ) – Market Insights, Epidemiology and Market Forecast-2028’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of WAIHA.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Study Period: 2017-2028
Warm autoimmune hemolytic anemia (wAIHA) is the most common form of autoimmune hemolytic anemia. Autoimmune Ahemolytic anemia (AIHA) is a rare acquired autoimmune disease, as a consequence of which the immune system attacks its red blood cells considering them foreign substances.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Warm Autoimmune Hemolytic Anemia (wAIHA) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practise/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
Click to know more about the report
Warm autoimmune hemolytic anemia Epidemiology
In 2017, as per the estimates by DelveInsight, Warm Autoimmune Haemolytic Anemia had affected 82,045 people approximately in the 7MM.
WAIHA affects 1 in 35,000 in North America. With a population of about 57 crores, WAIHA is a cause of distress to many living in that continent only, let alone worldwide.
The Warm Autoimmune Hemolytic Anemia (wAIHA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
wAIHA Epidemiology Segmentation
- Total prevalent cases of wAIHA
- Total prevalent cases of wAIHA
- Type-specific prevalent cases of wAIHA
- Gender-specific prevalent cases of wAIHA
Warm Autoimmune Hemolytic Anemia Market Outlook
The Warm Autoimmune Hemolytic Anemia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analysing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
The Warm autoimmune hemolytic anemia treatment landscape includes corticosteroids, splenectomy and conventional immunosuppressive drugs to keep the patient clinically comfortable and to prevent “hemolytic crises” with the use of medical interventions with the lowest possible short- and long-term side effects.
Warm Autoimmune Hemolytic Anemia Pipeline
Some of the key pharma players in the Warm autoimmune hemolytic anemia market are Rigel, Apellis Pharmaceuticals, Momenta Pharmaceuticals, Immunovant, Alexion and others are expected to launch their candidates in the WAIHA market in the coming decade.
Warm autoimmune hemolytic anemia market comprises a strong pipeline including fostamatinib (Rigel Pharmaceuticals), APL-2 (Apellis Pharmaceuticals, Inc.), M281 (Momenta Pharmaceuticals), ALXN1830 (Alexion Pharmaceuticals), IMVT-1401 (Immunovant) and others are anticipated to impact the WAIHA market positively.
However, DelveInsight analysts estimate that fostamatinib – a candidate of Rigel – will significantly occupy the Warm autoimmune hemolytic anemia market share for the forecast period (2019-2028).
This segment gives a thorough the detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Request for sample pages from here.
Warm Autoimmune Hemolytic Anemia Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
1. Key Insights
2. wAIHA Market Overview at a Glance
3. Disease Background and Overview
4. Epidemiology and Patient Population
5. Country Wise-Epidemiology of wAIHA
6. Treatment and Management of WAIHA
7. Unmet Needs
8. Emerging Therapies
9. wAIHA: 7 Major Market Analysis
10. Market Outlook by Country
11. EU-5 Countries: Market Outlook
12. Japan: Market Outlook
13. Market Drivers
14. Market Barriers
15. Appendix
16. DelveInsight Capabilities
17. Disclaimer
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/